Advertisement

Table of Contents

Breaking Advances

Reviews

Priority Reports

  • Priority Reports
    Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells
    Arun Satelli, Abhisek Mitra, Jeffry J. Cutrera, Marcos Devarie, Xueqing Xia, Davis R. Ingram, Denada Dibra, Neeta Somaiah, Keila E. Torres, Vinod Ravi, Joseph A. Ludwig, Eugenie S. Kleinerman and Shulin Li
    Cancer Res March 15 2014 74 (6) 1645-1650; DOI:10.1158/0008-5472.CAN-13-1739

    This study describes the first universal and specific marker to detect circulating sarcoma cells in the blood, with the capability to detect any type of sarcoma, offering a key prognostic tool to monitor cancer metastasis and relapse in sarcoma patients.

  • Priority Reports
    PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer
    John R. Prensner, Wei Chen, Matthew K. Iyer, Qi Cao, Teng Ma, Sumin Han, Anirban Sahu, Rohit Malik, Kari Wilder-Romans, Nora Navone, Christopher J. Logothetis, John C. Araujo, Louis L. Pisters, Ashutosh K. Tewari, Christine E. Canman, Karen E. Knudsen, Naoki Kitabayashi, Mark A. Rubin, Francesca Demichelis, Theodore S. Lawrence, Arul M. Chinnaiyan and Felix Y. Feng
    Cancer Res March 15 2014 74 (6) 1651-1660; DOI:10.1158/0008-5472.CAN-13-3159

    A long noncoding RNA known to be oncogenic is found to promote cell death during genotoxic stress, suggesting a novel clinical correlation between this little-understood class of RNAs and genotoxic cancer therapies.

Integrated Systems and Technologies

  • Integrated Systems and Technologies
    Cancer-Associated Mutations in Healthy Individuals: Assessing the Risk of Carcinogenesis
    Ignacio A. Rodriguez-Brenes, Natalia L. Komarova and Dominik Wodarz
    Cancer Res March 15 2014 74 (6) 1661-1669; DOI:10.1158/0008-5472.CAN-13-1452

    Understanding how limits on cellular replication influence the fate of altered but nonneoplastic cells in healthy tissue may make it possible to estimate the risk posed by cancer-associated mutations found in healthy individuals.

Microenvironment and Immunology

Molecular and Cellular Pathobiology

  • Molecular and Cellular Pathobiology | AuthorChoice
    FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway
    Aifu Lin, Hai-long Piao, Li Zhuang, Dos D. Sarbassov, Li Ma and Boyi Gan
    Cancer Res March 15 2014 74 (6) 1682-1693; DOI:10.1158/0008-5472.CAN-13-1729

    A transcription factor that functions in tumor suppression was unexpectedly found to instead promote renal tumor growth under conditions of PI3K–AKT inhibition, with implications on how to improve antitumor responses.

  • Molecular and Cellular Pathobiology
    Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer
    Gunnar Steinert, Sebastian Schölch, Thomas Niemietz, Naoki Iwata, Sebastián A. García, Bianca Behrens, Anita Voigt, Matthias Kloor, Axel Benner, Ulrich Bork, Nuh N. Rahbari, Markus W. Büchler, Nikolas H. Stoecklein, Jürgen Weitz and Moritz Koch
    Cancer Res March 15 2014 74 (6) 1694-1704; DOI:10.1158/0008-5472.CAN-13-1885

    These results show that circulating colon tumor cells are genetically different from the primary colon tumor, exhibiting an immunosuppressive phenotype that enables them to evade immune eradication.

  • Molecular and Cellular Pathobiology
    UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells
    Jae-Hwan Kim, Amrish Sharma, Shilpa S. Dhar, Sung-Hun Lee, Bingnan Gu, Chia-Hsin Chan, Hui-Kuan Lin and Min Gyu Lee
    Cancer Res March 15 2014 74 (6) 1705-1717; DOI:10.1158/0008-5472.CAN-13-1896

    These findings show how coordinated regulation of gene expression programs by two distinct epigenetic modifiers drives malignant properties in breast cancer cells.

  • Molecular and Cellular Pathobiology
    Neuroplastic Changes Occur Early in the Development of Pancreatic Ductal Adenocarcinoma
    Rachelle E. Stopczynski, Daniel P. Normolle, Douglas J. Hartman, Haoqiang Ying, Jennifer J. DeBerry, Klaus Bielefeldt, Andrew D. Rhim, Ronald A. DePinho, Kathryn M. Albers and Brian M. Davis
    Cancer Res March 15 2014 74 (6) 1718-1727; DOI:10.1158/0008-5472.CAN-13-2050

    These studies show that changes in the peripheral nervous system occur early during tumor development and may play an important role in disease progression.

  • Molecular and Cellular Pathobiology
    HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT
    Ji Heon Noh, Hyun Jin Bae, Jung Woo Eun, Qingyu Shen, Se Jin Park, Hyung Seok Kim, Boas Nam, Woo Chan Shin, Eun Kyung Lee, Kyungbun Lee, Ja-Jun Jang, Won Sang Park, Jung Young Lee and Suk Woo Nam
    Cancer Res March 15 2014 74 (6) 1728-1738; DOI:10.1158/0008-5472.CAN-13-2109

    This study of a histone deacetylase that is essential for mitogenic signaling in liver cancers may offer a new interventional target for more effective therapy.

  • Molecular and Cellular Pathobiology
    p16INK4a Impairs Homologous Recombination–Mediated DNA Repair in Human Papillomavirus–Positive Head and Neck Tumors
    Rüveyda Dok, Peter Kalev, Evert Jan Van Limbergen, Layka Abbasi Asbagh, Iria Vázquez, Esther Hauben, Anna Sablina and Sandra Nuyts
    Cancer Res March 15 2014 74 (6) 1739-1751; DOI:10.1158/0008-5472.CAN-13-2479

    These findings reveal an unexpected function of the tumor suppressor p16INK4A in promoting the homologous recombination pathway of DNA repair, suggesting that p16INK4A status in head and neck cancer patients may offer an independent marker to predict their response to radiotherapy.

Therapeutics, Targets, and Chemical Biology

  • Therapeutics, Targets, and Chemical Biology
    Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
    Fengting Yan, Lapo Alinari, Mark E. Lustberg, Ludmila Katherine Martin, Hector M. Cordero-Nieves, Yeshavanth Banasavadi-Siddegowda, Selene Virk, Jill Barnholtz-Sloan, Erica Hlavin Bell, Jeffrey Wojton, Naduparambil K. Jacob, Arnab Chakravarti, Michal O. Nowicki, Xin Wu, Rosa Lapalombella, Jharna Datta, Bo Yu, Kate Gordon, Amy Haseley, John T. Patton, Porsha L. Smith, John Ryu, Xiaoli Zhang, Xiaokui Mo, Guido Marcucci, Gerard Nuovo, Chang-Hyuk Kwon, John C. Byrd, E. Antonio Chiocca, Chenglong Li, Said Sif, Samson Jacob, Sean Lawler, Balveen Kaur and Robert A. Baiocchi
    Cancer Res March 15 2014 74 (6) 1752-1765; DOI:10.1158/0008-5472.CAN-13-0884

    This study presents a novel candidate prognostic and therapeutic target in aggressive brain cancers, with implications for understanding the basis for poor patient survival.

  • Therapeutics, Targets, and Chemical Biology
    Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent Pathway
    Rosa Martín-Pérez, Carmen Palacios, Rosario Yerbes, Ana Cano-González, Daniel Iglesias-Serret, Joan Gil, Mauricio J. Reginato and Abelardo López-Rivas
    Cancer Res March 15 2014 74 (6) 1766-1777; DOI:10.1158/0008-5472.CAN-13-1747

    These findings offer a rationale for the therapeutic exploration of treatments inducing ER stress against mutant ERBB2-expressing breast tumor cells.

  • Therapeutics, Targets, and Chemical Biology | AuthorChoice
    ATDC/TRIM29 Phosphorylation by ATM/MAPKAP Kinase 2 Mediates Radioresistance in Pancreatic Cancer Cells
    Lidong Wang, Huibin Yang, Phillip L. Palmbos, Gina Ney, Taylor Ann Detzler, Dawn Coleman, Jacob Leflein, Mary Davis, Min Zhang, Wenhua Tang, J. Kevin Hicks, Corey M. Helchowski, Jayendra Prasad, Theodore S. Lawrence, Liang Xu, Xiaochun Yu, Christine E. Canman, Mats Ljungman and Diane M. Simeone
    Cancer Res March 15 2014 74 (6) 1778-1788; DOI:10.1158/0008-5472.CAN-13-2289

    These findings link a TRIM family protein that binds DNA and p53 to radioresistance in pancreatic cancer, suggesting its candidacy as a therapeutic target to improve the efficacy of DNA-damaging treatments used to treat this disease.

  • Therapeutics, Targets, and Chemical Biology | AuthorChoice
    Alarmin IL-33 Acts as an Immunoadjuvant to Enhance Antigen-Specific Tumor Immunity
    Daniel O. Villarreal, Megan C. Wise, Jewell N. Walters, Emma L. Reuschel, Min Joung Choi, Nyamekye Obeng-Adjei, Jian Yan, Matthew P. Morrow and David B. Weiner
    Cancer Res March 15 2014 74 (6) 1789-1800; DOI:10.1158/0008-5472.CAN-13-2729

    These findings offer a preclinical proof of concept that IL-33 improves the immune potency of tumor vaccines, promoting tumor cell clearance and regressions to fully empower cancer immunotherapy.

  • Therapeutics, Targets, and Chemical Biology
    miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway
    Jian-Jun Zhao, Jianhong Lin, Di Zhu, Xujun Wang, Daniel Brooks, Ming Chen, Zhang-Bo Chu, Kohichi Takada, Bryan Ciccarelli, Samir Admin, Jianguo Tao, Yu-Tzu Tai, Steven Treon, Geraldine Pinkus, Winston Patrick Kuo, Teru Hideshima, Mary Bouxsein, Nikhil Munshi, Kenneth Anderson and Ruben Carrasco
    Cancer Res March 15 2014 74 (6) 1801-1813; DOI:10.1158/0008-5472.CAN-13-3311-T

    These findings offer a preclinical rationale to explore delivery of a tumor-suppressive microRNA as an effective therapeutic strategy to eradicate multiple myeloma cells.

Tumor and Stem Cell Biology

  • Tumor and Stem Cell Biology
    Id2 Mediates Oligodendrocyte Precursor Cell Maturation Arrest and Is Tumorigenic in a PDGF-Rich Microenvironment
    Matthew C. Havrda, Brenton R. Paolella, Cong Ran, Karola S. Jering, Christina M. Wray, Jaclyn M. Sullivan, Audrey Nailor, Yasuyuki Hitoshi and Mark A. Israel
    Cancer Res March 15 2014 74 (6) 1822-1832; DOI:10.1158/0008-5472.CAN-13-1839

    This study of distinct subsets of adult tissue progenitors points to a maturation arrest of oligodendroglial precursor cells in the pathogenesis of PDGF-dependent brain tumors.

  • Tumor and Stem Cell Biology
    Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma
    Rebecca Favaro, Irene Appolloni, Serena Pellegatta, Alexandra Badiola Sanga, Pierfrancesco Pagella, Eleonora Gambini, Federica Pisati, Sergio Ottolenghi, Maria Foti, Gaetano Finocchiaro, Paolo Malatesta and Silvia K. Nicolis
    Cancer Res March 15 2014 74 (6) 1833-1844; DOI:10.1158/0008-5472.CAN-13-1942

    These findings define an immunotherapeutic target for treatment of a form of brain malignancy, which acts by depleting cancer stem-like cells required to sustain the malignancy in a mouse model system.

  • Tumor and Stem Cell Biology | AuthorChoice
    Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma
    Jian Hong, Yunfei Yuan, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai and Raymond T. Chung
    Cancer Res March 15 2014 74 (6) 1845-1856; DOI:10.1158/0008-5472.CAN-13-2104

    These findings define opposing functions of the two isoforms of the SYK kinase in liver cancer, with the larger isoform enhancing invasion and the smaller isoform enhancing metastasis, patterns that in patient specimens offer strong predictors of overall survival.

  • Tumor and Stem Cell Biology
    MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors
    Paolo Luraghi, Gigliola Reato, Elia Cipriano, Francesco Sassi, Francesca Orzan, Viola Bigatto, Francesca De Bacco, Elena Menietti, May Han, William M. Rideout III, Timothy Perera, Andrea Bertotti, Livio Trusolino, Paolo M. Comoglio and Carla Boccaccio
    Cancer Res March 15 2014 74 (6) 1857-1869; DOI:10.1158/0008-5472.CAN-13-2340-T

    Using cancer stem-like cells isolated directly from metastatic colorectal patients, this study reveals the importance of both EGFR and MET signaling and offers a strong preclinical proof of concept for concurrent targeting of both of these receptors in the clinical setting.

  • Tumor and Stem Cell Biology
    p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
    Jian Zhong, Liya Ding, Laura R. Bohrer, Yunqian Pan, Ping Liu, Jun Zhang, Thomas J. Sebo, R. Jeffrey Karnes, Donald J. Tindall, Jan van Deursen and Haojie Huang
    Cancer Res March 15 2014 74 (6) 1870-1880; DOI:10.1158/0008-5472.CAN-13-2485

    This article identifies a key determinant in degradation of the androgen receptor, highlighting its importance as a candidate therapeutic target in managing prostate cancers marked by loss of the tumor suppressor PTEN.

Correction

Back to top
Cancer Research: 74 (6)
March 2014
Volume 74, Issue 6

Sign up for alerts

Issue Highlights

Jump to

Advertisement